S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Fusion Pharmaceuticals (FUSN) Stock Forecast & Price Target

$5.82
+0.08 (+1.39%)
(As of 12/8/2023 ET)
Compare
Today's Range
$5.68
▼
$5.93
50-Day Range
$2.48
▼
$5.82
52-Week Range
$2.30
▼
$5.93
Volume
497,550 shs
Average Volume
256,741 shs
Market Capitalization
$421.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.20
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Fusion Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 6 Analyst Ratings

Analysts' Consensus Price Target

$12.20
109.62% Upside
High Forecast$13.00
Average Forecast$12.20
Low Forecast$10.00
TypeCurrent Forecast
12/10/22 to 12/10/23		1 Month Ago
11/10/22 to 11/10/23		3 Months Ago
9/11/22 to 9/11/23		1 Year Ago
12/10/21 to 12/10/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.20$11.17$9.50$11.67
Predicted Upside109.62% Upside248.60% Upside202.07% Upside309.36% Upside
Get Fusion Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.


FUSN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FUSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fusion Pharmaceuticals Stock vs. The Competition

TypeFusion PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside109.62% Upside737.03% Upside3,819.11% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform$13.00+189.53%
10/3/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$13.00+285.76%
9/28/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$13.00+392.42%
8/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$13.00 ➝ $12.00+270.37%
2/13/2023Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$19.00 ➝ $10.00+201.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:28 AM ET.












FUSN Price Target - Frequently Asked Questions

What is Fusion Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Fusion Pharmaceuticals stock is Buy based on the current 6 buy ratings for FUSN. The average twelve-month price prediction for Fusion Pharmaceuticals is $12.20 with a high price target of $13.00 and a low price target of $10.00. Learn more on FUSN's analyst rating history.

Do Wall Street analysts like Fusion Pharmaceuticals more than its competitors?

Analysts like Fusion Pharmaceuticals more than other Medical companies. The consensus rating for Fusion Pharmaceuticals is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how FUSN compares to other companies.

Does Fusion Pharmaceuticals's stock price have much upside?

According to analysts, Fusion Pharmaceuticals's stock has a predicted upside of 257.56% based on their 12-month stock forecasts.

What analysts cover Fusion Pharmaceuticals?

Fusion Pharmaceuticals has been rated by B. Riley, Oppenheimer, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:FUSN) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -